Inside Innovation

Four years after its launch, Seattle-based company Sana Biotechnology announced FDA approval to start clinical trials for its allogeneic CAR-T cell therapy treatment. The SC291

Seattle-based startup Myosana Therapeutics raised $5 million to develop an early-stage candidate treatment for Duchenne muscular dystrophy (DMD).  DMD is caused by mutations in the largest

Seattle-based biotech Parse Biosciences has moved to a 34,000-square-foot facility at the new Dexter Yard development in South Lake Union. The new building is an

Seattle is the place to be in 2023, filled with lots of optimism, new beginnings and exciting breakthroughs for the year ahead. Investments are running

Washington-based AGC Biologics has been chosen to help manufacture Provention Bio’s Type 1 juvenile diabetes treatment. The treatment had been in development for over 36

The Bill & Melinda Gates Foundation and the Ballmer family have gifted UW Medicine $20 million in honor of former dean, Dr. Paul Ramsey. The

A new report from WalletHub ranks Seattle as the best overall metro area for STEM professionals in the U.S. The rankings were determined based on

After analyzing over 200,000 human stem cells in 3D high resolution, researchers at Seattle’s Allen Institute for Cell Science and their colleagues developed an approach

The Seattle Inno and the Puget Sound Business Journal recently announced the 23 startups to watch in 2023. The list was compiled by account factors such as revenue growth,

In an exclusive interview with Investment Reports, Marc Cummings, President and CEO of Life Science Washington, shared details on the state of the life science

The Kirkland-based company, Cardiac Dimensions, announced a $35 million Series D round with plans to grow its team and advance through U.S. clinical trials for

Following a positive release of clinical data from a phase 2b testing trial of zanidatamab, Zymeworks, based in the Pacific Northwest, has secured $350 million